Where we at?, page-137

I circled back to FB's post from earlier in the year. He was spot on with the appointment of an independent director with significant equity. We can only assume the comment about corporates being all over this, looking at non-dilutive funding, etc has merit. Although there will be a price to pay no doubt.

As Mozz said, the dominoes need to fall in place sequentially. FDA approval, funding, options in the money, deals, etc. There is potential for a quicķ turnaround, we can only hope.

We will probably have about $10-$15mn in the tin at June 30 (unless other funding sorted), so it is all coming to a crux. Might be best to go on holiday in June as tax loss selling could be brutal, especially if no progress with FDA.